News

The FDA approval will allow Genzyme to begin the process of returning patients to full dosing (1mg/kg) levels. According to the company, all patients in the US currently

The randomised study has evaluated the safety and efficacy of standard-dose ZEVALIN 14 days prior to ASCT, followed by high-dose BEAM chemotherapy (Z-BEAM) and ASCT in refractory/relapsed aggressive

The ANDA filing involved contributions from both Perrigo and Impax who will share costs and benefits of this project. Astepro Nasal Spray is a prescription medicine for people

As Sanguine increases its presence on the biomarker development front, the company’s clients will demand bioassay development services, and TGA is now well positioned to receive a larger

The Phase III pivotal study of TR701-112 is the first of two pivotal Phase II trials designed to support the filing of a NDA with the FDA as

Through the agreement with UH Bristol, PAREXEL expands alliance network to support early phase patient studies. UH Bristol, a provider of medical and dental teaching, is a research

The data has suggested that repeated cycles of fractionated doses of clivatuzumab tetraxetan, labeled with yttrium-90 (90Y) and given in combination with gemcitabine, demonstrated therapeutic activity in pancreatic

The new patent has a scheduled expiry date in 2028, not including any potential regulatory extensions. The HuCAL-derived, fully human antibody is currently being tested in a Phase

WEP has developed two proprietary biopolymer technologies, PolyPEG and GlycoPol. WEP has agreements with global pharmaceutical and biotechnology companies for the evaluation of PolyPEG or GlycoPol and the